New drug combo tested for aggressive pancreatic cancer
NCT ID NCT07176702
Summary
This study is testing whether adding a new antibody drug called HLX22 to the standard treatment (trastuzumab plus chemotherapy) works better for people with a specific type of metastatic pancreatic cancer that tests positive for HER2. It will involve about 45 adults who have not had prior treatment for their advanced cancer. The main goal is to see if this three-drug combination shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PDAC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Nanjing, 210008, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200233, China
Conditions
Explore the condition pages connected to this study.